SEARCH

Current Edition

blood

Merck study results signal blood cancer potential for new type of immunotherapy

For years, Merck & Co. has had an upper hand over its chief cancer drug competitor Bristol Myers Squibb. In March, however, Bristol Myers beat …

Continue Reading →
Business

Merck brings former executive back to lead ex-US pharmaceuticals business

Dive Brief: Merck has tapped a former executive, Joseph Romanelli, to run the company’s pharmaceutical business in markets outside the U.S. after restructuring its human …

Continue Reading →
cancer

How Merck’s ‘puzzling’ results could impact immunotherapy’s role in early lung cancer

An immunotherapy from Merck & Co. is the latest drug of its kind to slow the return of lung cancer in clinical testing, though mixed …

Continue Reading →
chronic

Merck drug for chronic cough rejected by FDA

Dive Brief: The Food and Drug Administration has rejected Merck & Co’s experimental drug for chronic cough, issuing the company a complete response letter for …

Continue Reading →
anxiety

M&A anxiety, Roche’s comeback plan and Vir’s omicron moment

The second day of the J.P. Morgan Healthcare Conference, much like the first, didn’t include the type of market-moving acquisitions or announcements that might break …

Continue Reading →
COVID-19 pills

COVID-19 pills from Pfizer, Merck authorized by FDA in major pandemic milestone

Paxlovid and molnupiravir are the first oral treatments for COVID-19, potentially valuable new tools as the fast-spreading omicron variant fuels a sharp surge in cases …

Continue Reading →
active ingredient

A worrisome safety signal slows Merck’s HIV ambitions

Currently, the world’s best-selling HIV medications are made up of at least three “active ingredients.” But recent years have seen increasing interest in treatments that …

Continue Reading →
clinical trial

FDA approves Merck’s Keytruda as first immunotherapy for early kidney cancer

Approval of Keytruda in this setting comes about six months after Merck revealed early results from a study called Keynote-564, which showed the immunotherapy could …

Continue Reading →
COVID-19 pill

US pays $1B to nearly double supply of Merck’s COVID-19 pill

Merck is now in a race with Pfizer to capture the upside of COVID-19 pills, which could soon play an outsized role in the next …

Continue Reading →
COVID-19

Merck wins UK authorization to sell first COVID-19 pill

U.K. regulators have once again moved faster than the Food and Drug Administration to approve a new medicine for COVID-19. The UK’s Medicines and Healthcare …

Continue Reading →
COVID-19

Merck agrees to license COVID-19 pill widely through pact with patent group

Merck’s pill has the potential to alter the course of the pandemic. Earlier this month, the company and partner Ridgeback Biotherapeutics released data showing molnupiravir …

Continue Reading →
19-64 age

CDC panel levels playing field for new Merck, Pfizer pneumonia vaccines

This is the first time government advisers have recommended routine use of a pneumococcal vaccine for certain risk groups within the 19-64 age bracket, a …

Continue Reading →
COVID-19

Gates Foundation pledges $120M to bring Merck COVID-19 drug to lower-income countries

The Gates Foundation hopes to reduce the gap in time between when wealthy countries and lower-income nations get access to needed medicines like molnupiravir. The …

Continue Reading →
cervical cancer

Merck advantage grows as FDA approves Keytruda for first-line cervical cancer

Merck’s Keytruda is the dominant cancer immunotherapy and, of the seven of its type that are approved, the only that’s cleared for use in cervical …

Continue Reading →
clinical trial

Merck, Ridgeback seek US clearance of first oral COVID-19 drug

Merck’s filing comes less than two weeks after the drugmaker showed molnupiravir lowered the risk of hospitalization or death by roughly 50% in a Phase …

Continue Reading →
cholesterol

Insurers sue Merck for ‘monopolistic scheme’ to delay generics of blockbuster cholesterol drug

Insurers Centene and Humana have sued Merck & Co., alleging the drugmaker’s “monopolistic scheme” delayed generic versions of its blockbuster cholesterol drug Zetia from coming …

Continue Reading →
AstraZeneca

As FDA scrutinizes immunotherapy approvals, Merck says Keytruda extends survival in liver cancer trial

The FDA has been under pressure to review the status of drugs granted accelerated approvals based on early data, as in some cases confirmatory trials …

Continue Reading →
ArQule

Merck wins approval for cancer drug acquired in 2019 biotech buyout

Peloton was one of a handful of cancer-focused biotech companies acquired since 2018 by Merck, which has sought to complement its top-selling immunotherapy Keytruda with …

Continue Reading →
advanced

Merck’s Keytruda gets approval in China for advanced melanoma

Melanoma is one of the fastest growing malignant cancers in China, increasing at an annual rate of 3-5 percent, which makes it one of the …

Continue Reading →
2

Merck inks deal with China’s Xian Janssen for type 2 diabetes drug

China has more than 114 million people living with diabetes, the largest number of any country in the world Global drug giant, Merck signed an …

Continue Reading →